As the trans-Tasman travel bubble opens, hygiene vigilance remains vital.

The Australia-New Zealand travel bubble starts today – a major boost for trans-Tasman tourism, business and family travel after a year disrupted by the COVID-19 pandemic.

Qantas and Jetstar are planning up to 122 flights per week, offering 52,000 seats on 15 routes across the ‘ditch’, while Air New Zealand reports record sales on trans-Tasman flights, and is preparing for a surge in Australia-Queenstown travel for the upcoming NZ ski season.

The trans-Tasman travel bubble is the first real test of international travel in this region during the pandemic, and its success is critical to the establishment of similar secure markets, with Australia-Singapore and New Zealand-Cook Islands both being considered.

But ensuring the success of travel bubbles – which have no quarantine requirements – will require continuation of strict public health protocols to minimise the risk of transmitting COVID-19, as sporadic outbreaks continue to occur, and vaccination schedules lag.

Australian biotechnology company Hygiene Labs is active in aviation protection, producing a long-lasting antimicrobial disinfectant treatment, which is verified to inactivate surface infections of Coronavirus for up to 28 days, minimising the chance of touch-transmission in airports or on aircraft.

The treatment has been listed by Australia’s medical products regulator, the Therapeutic Goods Administration, has been introduced by aviation partners including Qantas, Fiji Airways, Nauru Airlines, Australia’s Royal Flying Doctor Service, and a major VIP operator, and is perfectly suited for the treatment of airport terminals and their public transport connections.

Hygiene Labs proudly supports the return of air travel.